BioCryst Pharmaceuticals Inc.

BCRX | NASDAQ

$8.92

+$0.16 (+1.83%)

Sep 22, 2026, 12:00 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Net Income	263.86M	-88.88M	-226.54M	-247.12M	-184.06M	-182.81M
Depreciation & Amortization	1.39M	1.25M	1.66M	1.44M	777K	748K
Stock-Based Compensation	85.07M	65.41M	55.62M	44.7M	34.64M	n/a
Other Working Capital	-76.26M	1.96M	-8.05M	-2.69M	-1.7M	2.66M
Other Non-Cash Items	36.46M	57.48M	106.53M	98.07M	-1.64M	17.98M
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	-56.9M	-87.28M	-32.4M	-58.95M	8.12M	26.88M
Operating Cash Flow	329.88M	-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
Capital Expenditures	-2.47M	-1.12M	-2.17M	-1.35M	-2.39M	-514K
Cash Acquisitions	-6.18M	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	-262.24M	-266.76M	-514.41M	-244.28M	-10.01M	-49.82M
Sales Maturities Of Investments	256.65M	320.48M	385.08M	117.4M	28.2M	43.48M
Other Investing Acitivies	550K	n/a	n/a	n/a	n/a	1K
Investing Cash Flow	-13.69M	52.59M	-131.5M	-128.24M	15.8M	-6.86M
Debt Repayment	-332.77M	-1.7M	58.38M	73.07M	293.87M	67.45M
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-8.85M	-4.09M	-26.24M	14.77M	15.73M	124.71M
Financial Cash Flow	-332.44M	-5.76M	32.49M	88.03M	359.67M	302.7M
Net Cash Flow	-103.32M	-6.12M	-193.79M	-201.5M	233.39M	158.63M
Free Cash Flow	327.41M	-53.14M	-97.31M	-163.2M	-144.54M	-137.73M
Adj. Free Cash Flow	242.35M	-118.56M	-152.92M	-207.9M	-179.18M	-137.73M
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a	-514K
Growth CapEx	-2.47M	-1.12M	-2.17M	-1.35M	-2.39M	n/a
Owner Earnings	329.88M	-52.02M	-95.14M	-161.85M	-142.16M	-137.73M